Ardelyx (ARDX) announced the appointment of Eric Foster as the company’s Chief Commercial Officer. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Foster will be responsible for leading all commercial strategies for the company’s two first-in-class medicines, IBSRELA and XPHOZAH, as well as supporting the development and launch of future commercial products. Most recently, Mr. Foster served as Senior Vice President and U.S. General Manager at Amgen (AMGN)
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDX:
- Ardelyx price target raised to $11 from $10 at H.C. Wainwright
- Ardelyx price target raised to $12 from $10 at Citi
- Ardelyx reports Q2 EPS (7c), consensus (11c)
- Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
- Ardelyx options imply 11.4% move in share price post-earnings